Intercept Pharmaceuticals Price Target Increased to $360.00 by Analysts at Oppenheimer (ICPT)
Research analysts at Oppenheimer increased their price objective on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $94.00 to $360.00 in a report released on Friday, StockRatingsNetwork reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 30.50% from the company’s current price.
In other Intercept Pharmaceuticals news, Insider Luciano Adorini sold 1,634 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $67.41, for a total transaction of $110,147.94. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Intercept Pharmaceuticals from $60.00 to $400.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Bank of America Corp. raised their price target on shares of Intercept Pharmaceuticals from $81.00 to $872.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at BMO Capital Markets raised their price target on shares of Intercept Pharmaceuticals to $270.00 in a research note to investors on Thursday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $296.00.
Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 275.87 on Friday. Intercept Pharmaceuticals has a 52 week low of $30.38 and a 52 week high of $305.00. The stock has a 50-day moving average of $66.99 and a 200-day moving average of $55.33. The company’s market cap is $5.334 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, November 14th. The company reported ($1.65) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.51) by $1.14. During the same quarter last year, the company posted ($1.86) earnings per share. On average, analysts predict that Intercept Pharmaceuticals will post $-3.45 earnings per share for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.